Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.74 |
| ▸ | HPGD | P15428 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.74 |
| ▸ | NPC1 | O15118 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.74 |
| ▸ | ESR1 | P03372 | 4/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.74 |
| ▸ | MAOA | P21397 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464671 | 0.90 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL12238015 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL16226987 | 0.85 | ALDH2 (0.81) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL29352944 | 0.85 | MAPT (1.00) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL19166 | 0.85 | MAPT (1.00) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL554056 | 0.85 | MAPT (1.00) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL551449 | 0.84 | MAPT (0.97) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL551801 | 0.84 | MAPT (0.97) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL551402 | 0.84 | MAPT (0.97) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A | |
| Genistein SCHEMBL31168045 | 0.84 | MAPT (0.97) | SMN1; SMN2HPGDALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2010-06-17 | — | — | US | disclosed |
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2010-06-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| EP-1721903-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | Novogen Research Pty. Ltd. (AU) | 2006-11-15 | — | — | EP | disclosed |
| EP-1210341-B1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2006-08-02 | — | — | EP | disclosed |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY. LTD. | 2006-05-18 | — | — | US | disclosed |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2004-07-29 | — | — | US | disclosed |
| EP-1210341-A4 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2003-06-11 | — | — | EP | disclosed |
| EP-1210341-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | Novogen Research Pty. Ltd. (AU) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017986-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2001-03-15 | — | — | WO | disclosed |
| US-4772627-A | AMORPHOUS DRUG AND ADSORBENT, IMPROVED DISSOLUTION AND ADSORPTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-20 | — | — | US | disclosed |
| EP-0129893-A2 | Ground mixture | Takeda Chemical Industries, Ltd. (JP) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | PMP22, NGF, GAP43 | SMN1; SMN2 24/4885HPGD 77/4885ALDH1A1 610/4885 |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, OAT, APOB | SMN1; SMN2 1044/4885HPGD 135/4885ALDH1A1 3385/4885 |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | SMN1; SMN2 3439/4885HPGD 239/4885ALDH1A1 2374/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | SMN1; SMN2 1044/4885HPGD 135/4885ALDH1A1 3385/4885 |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | SMN1; SMN2 3263/4885HPGD 279/4885ALDH1A1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.